Megan Cole

Nov 1, 2024 | science.org | Spencer Shelton |Megan Cole |Mengjie Zhang |Hao Ren

AbstractHighly efficient bifacial organic solar cells (OSCs) have not been reported due to limited thickness of the active layer in conventional configurations, not allowing for efficient harvesting of front sunlight and albedo light. Here, bifacial OSCs are reported with efficiency higher than the monofacial counterparts.

Nov 1, 2024 | science.org | Spencer Shelton |Megan Cole |Mengjie Zhang |Panayiotis Anastasiou

AbstractKirsten rat sarcoma virus (KRAS)–G12C inhibition causes remodeling of the lung tumor immune microenvironment and synergistic responses to anti–PD-1 treatment, but only in T cell infiltrated tumors. To investigate mechanisms that restrain combination immunotherapy sensitivity in immune-excluded tumors, we used imaging mass cytometry to explore cellular distribution in an immune-evasive KRAS mutant lung cancer model.

Nov 1, 2024 | science.org | Spencer Shelton |Megan Cole |Mengjie Zhang |Jesus Serrano Redondo |Jesús Redondo

AbstractIn polarizable materials, electronic charge carriers interact with the surrounding ions, leading to quasiparticle behavior. The resulting polarons play a central role in many materials properties including electrical transport, interaction with light, surface reactivity, and magnetoresistance, and polarons are typically investigated indirectly through these macroscopic characteristics.

Nov 1, 2024 | science.org | Spencer Shelton |Megan Cole |Mengjie Zhang |Zheng Wang

AbstractHarnessing the immunogenic potential of senescent tumor cells provides an opportunity to remodel tumor microenvironment (TME) and boost antitumor immunity. However, this potential needs to be sophisticatedly wielded to avoid additional immunosuppressive capacity of senescent cells.

Apr 13, 2024 | biorxiv.org | Megan Cole |Panayiotis Anastasiou |Claudia Lee |Chris Moore

AbstractWe recently showed that lung tumor specific KRAS-G12C inhibition causes remodelling of the tumor immune microenvironment from cold to hot. As a result, KRAS-G12C inhibition is able to synergise with anti-PD-1 treatment, but only in tumor models that were already moderately responsive to immune checkpoint blockade at baseline.